Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases | Ophthalmology Times

This discussion centers on real-world comparisons between aflibercept 2 mg and the newer 8 mg formulation, focusing on drying efficacy, durability, and patient experience. Clinicians agree that aflibercept 8 mg offers a clear advantage in retinal fluid control and treatment predictability—particularly in patients with more resistant disease. The increased dose allows many patients to safely extend dosing intervals from 8 to 10 or even 12 weeks without compromising outcomes. Panelists emphasize the practical benefit of maintaining the same familiar molecule while offering an “upgrade” that patients easily understand and accept, simplifying adherence conversations. In diabetic macular edema (DME), the higher molar dose is especially impactful, leading to faster resolution of retinal fluid and potentially better visual outcomes by minimizing long-term fluid exposure. Overall, the experts conclude that aflibercept 8 mg meaningfully improves efficiency and durability while reducing treatment burden across diverse retinal vascular disease populations.